Literature DB >> 23930097

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.

.   

Abstract

Entities:  

Year:  2013        PMID： 23930097      PMCID： PMC3736777     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  8 in total

1.  Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.

Authors:  L Kleinman; M W Zodet; Z Hakim; J Aledort; C Barker; K Chan; L Krupp; D Revicki
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Authors:  M Lindh; M Lagging; B Arnholm; A Eilard; S Nilsson; G Norkrans; J Söderholm; T Wahlberg; R Wejstål; J Westin; K Hellstrand
Journal:  J Viral Hepat       Date:  2011-01-13       Impact factor: 3.728

3.  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

Authors:  Kris V Kowdley; Eric Lawitz; Israel Crespo; Tarek Hassanein; Mitchell N Davis; Michael DeMicco; David E Bernstein; Nezam Afdhal; John M Vierling; Stuart C Gordon; Jane K Anderson; Robert H Hyland; Hadas Dvory-Sobol; Di An; Robert G Hindes; Efsevia Albanis; William T Symonds; M Michelle Berrey; David R Nelson; Ira M Jacobson
Journal:  Lancet       Date:  2013-03-15       Impact factor: 79.321

4.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

5.  A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-06

6.  The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

Authors:  Tarek Hassanein; Graham Cooksley; Mark Sulkowski; Coleman Smith; George Marinos; Ming-Yang Lai; Giuseppe Pastore; Rafael Trejo-Estrada; Ana Horta E Vale; Neil Wintfeld; Jesse Green
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

7.  PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Authors:  Angela M Lam; Eisuke Murakami; Christine Espiritu; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Veronique Zennou; Nigel Bourne; Justin G Julander; John D Morrey; Donald F Smee; David N Frick; Julie A Heck; Peiyuan Wang; Dhanapalan Nagarathnam; Bruce S Ross; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

8.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Authors:  Edward J Gane; Catherine A Stedman; Robert H Hyland; Xiao Ding; Evguenia Svarovskaia; William T Symonds; Robert G Hindes; M Michelle Berrey
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245
  8 in total
  5 in total

1.  Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.

Authors:  Lin-Zhi Chen; John P Sabo; Elsy Philip; Lois Rowland; Yan Mao; Bachir Latli; Diane Ramsden; Debra A Mandarino; Rucha S Sane
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 2.  New treatments for chronic hepatitis C: an overview for paediatricians.

Authors:  Daniele Serranti; Giuseppe Indolfi; Massimo Resti
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

3.  Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors.

Authors:  Mahreen Arshad; Feifei Wei; David A Nelsen
Journal:  Antivir Ther       Date:  2015-08-26

4.  The current state and future prospects of chronic hepatitis C virus infection treatment.

Authors:  Christopher Moore; Josh Levitsky
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.663

5.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.